Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

Whoever's closest to the consumer will be the gatekeeper of the industry.

Principal, Health and Life Sciences, Organizational Effectiveness, Oliver Wyman
Principal, Oliver Wyman
Senior Consultant, Oliver Wyman

There's big buzz around consumer behavior driving outcomes. But clinical data doesn't yet align with behavioral data.

Partner, Health & Life Sciences, Oliver Wyman

Pharma companies and providers in search of better solutions must look to the patient experience for answers.

Partner, Digital & Analytics, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

2018 was a big year for industry news. Here's what might happen next in artificial intelligence, the 2020 presidential election, pharma, and more.

Partner, Health and Life Sciences, Oliver Wyman
Managing Partner, Americas, Oliver Wyman

Some of our 2018 predictions on consolidation, pharma, and investment came true, while others were less predictable.

Director, Marsh & McLennan Advantage, Healthcare

Insights in your inbox

Subscribe

Those challengers who address critical patient needs beyond traditional treatment will become a force to be reckoned with.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

From Walmart to Amazon to 23andMe, these 11 market scenarios paint a picture of what disruption looks like, both in and out of healthcare.

Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Chief Strategy Officer, BCBS of Massachusetts
Partner, Health & Life Sciences, Oliver Wyman

Purposeful collaboration will help more people understand how their daily decisions dictate their health.

Director, Oliver Wyman Health Innovation Center, Oliver Wyman

The key to measurement-based digital mental healthcare intervention and assessment? A patient's smartphone.

Traditional retailers are now getting into the health business. What does it all mean, and where should corporate directors focus next?

Partner, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe